share_log

Insiders Were the Key Beneficiaries as Tuoxin Pharmaceutical Group Co.,Ltd.'s (SZSE:301089) Market Cap Rises to CN¥4.4b

Insiders Were the Key Beneficiaries as Tuoxin Pharmaceutical Group Co.,Ltd.'s (SZSE:301089) Market Cap Rises to CN¥4.4b

隨着拓新藥業集團股份有限公司(深圳證券交易所:301089)的市值上升至44億元人民幣,內部人成爲主要受益者。
Simply Wall St ·  08/16 20:07

Key Insights

主要見解

  • Insiders appear to have a vested interest in Tuoxin Pharmaceutical GroupLtd's growth, as seen by their sizeable ownership
  • 52% of the business is held by the top 5 shareholders
  • Using data from company's past performance alongside ownership research, one can better assess the future performance of a company
  • 從持有現象來看,內部人員對拓新藥業集團有濃厚的興趣。
  • 前五大股東持有該公司52%的股份。
  • 通過公司過去的業績數據和股權研究,人們可以更好地評估一家公司的未來表現。

If you want to know who really controls Tuoxin Pharmaceutical Group Co.,Ltd. (SZSE:301089), then you'll have to look at the makeup of its share registry. With 55% stake, individual insiders possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果您想了解真正控制拓新藥業集團股份有限公司(SZSE:301089)的人,請查看其股權登記簿的組成。根據持股比例來看,個人內部人員擁有公司的最大股份,約爲55%。這意味着,如果股票上漲(或出現下行趨勢),該團體將獲得最大的利益。

As a result, insiders scored the highest last week as the company hit CN¥4.4b market cap following a 11% gain in the stock.

因此,由於該股票上漲11%,上週內部人員的得分最高,公司市值達到了44億人民幣。

In the chart below, we zoom in on the different ownership groups of Tuoxin Pharmaceutical GroupLtd.

在下面的圖表中,我們着重研究了拓新藥業集團股份有限公司的不同所有權集團。

big
SZSE:301089 Ownership Breakdown August 17th 2024
SZSE:301089所有權結構2024年8月17日

What Does The Institutional Ownership Tell Us About Tuoxin Pharmaceutical GroupLtd?

機構投資者持股比例告訴我們什麼,關於拓新藥業集團股份有限公司?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構通常在向自己的投資者報告時會針對一個基準進行衡量,因此一旦某隻股票被納入主要指數,他們通常會更加熱衷於該股票。我們預計大多數公司都會有一些機構在登記簿上,尤其是那些正在增長的公司。

Since institutions own only a small portion of Tuoxin Pharmaceutical GroupLtd, many may not have spent much time considering the stock. But it's clear that some have; and they liked it enough to buy in. So if the company itself can improve over time, we may well see more institutional buyers in the future. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too.

由於機構投資者僅擁有拓新藥業集團股份有限公司的一小部分,因此許多人可能沒有花費太多時間考慮股票。但很明顯,一些人喜歡它並買入了它。因此,如果公司本身能夠隨着時間的推移而改善,我們很可能會在未來看到更多的機構買家。有時候我們會看到一些大型機構想要同時購買某個股票時,股價飆升。您可以查看下面的收入和營業收入歷史記錄,以考慮更多機構投資者是否會想購買該股票。當然,還有許多其他要考慮的因素。

big
SZSE:301089 Earnings and Revenue Growth August 17th 2024
SZSE:301089營業收入和收入增長2024年8月17日

We note that hedge funds don't have a meaningful investment in Tuoxin Pharmaceutical GroupLtd. Xining Yang is currently the largest shareholder, with 27% of shares outstanding. In comparison, the second and third largest shareholders hold about 14% and 4.2% of the stock. Yuying Cai, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.

我們注意到對於拓新藥業集團股份有限公司,對沖基金並沒有實質性的投資。現有股份中,楊西寧目前是最大的股東,持有27%的股份。相比之下,第二大和第三大股東持有約14%和4.2%的股份。第三大股東蔡玉英也恰好擔任董事會成員。

To make our study more interesting, we found that the top 5 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

爲了使我們的研究更有趣,我們發現前5位股東控制了該公司超過一半的股份,這意味着該組人對公司的決策具有相當大的影響力。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.

研究公司的機構所有權可以爲您的研究增加價值,但同時調查分析師建議也是很好的做法,以更深入地了解股票的預期表現。我們目前沒有發現任何關於該公司的分析師報道,因此該公司不太可能被廣泛持有。

Insider Ownership Of Tuoxin Pharmaceutical GroupLtd

拓新藥業集團股份有限公司內部人員持股

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

內部人員的定義在不同國家之間可能略有不同,但董事會成員始終計數。公司管理層回答董事會,在此應代表股東利益。值得注意的是,有時高級管理人員也在董事會上。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。

It seems that insiders own more than half the Tuoxin Pharmaceutical Group Co.,Ltd. stock. This gives them a lot of power. That means they own CN¥2.4b worth of shares in the CN¥4.4b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

似乎內部人員擁有拓新藥業集團股份有限公司超過一半的股份。這賦予了他們很大的權力。這意味着他們擁有該44億公司中價值24億元人民幣的股份。這具有相當大的意義。很高興看到這樣的投資水平。您可以在此處查看這些內部人員是否最近購買。

General Public Ownership

一般大衆所有權

The general public, who are usually individual investors, hold a 41% stake in Tuoxin Pharmaceutical GroupLtd. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

普通公衆,通常是個人投資者,持有拓新藥業集團股份有限公司的41%股份。這種所有權的大小雖然相當可觀,但如果決策與其他大股東不同步,則可能無法改變公司政策。

Next Steps:

下一步:

It's always worth thinking about the different groups who own shares in a company. But to understand Tuoxin Pharmaceutical GroupLtd better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Tuoxin Pharmaceutical GroupLtd .

了解一家公司擁有股份的不同群體總是值得考慮的。但是爲了更好地了解拓新藥業集團股份有限公司,我們需要考慮許多其他因素。爲此,您應該知道我們發現了拓新藥業集團股份有限公司的1種警告信號。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,您可能會在其他地方找到一項出色的投資。因此,請查看此免費的有趣公司列表。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論